Guerbet receives new Lipiodol indication in Denmark

By staff writers

November 20, 2019 -- Contrast agent developer Guerbet has received approval for a new indication for its Lipiodol Ultra Fluid ultrasound contrast agent in Denmark. Lipiodol is now approved in Denmark for use in conventional transarterial chemoembolization (cTACE) procedures.

Specifically, the approval covers the use of Lipiodol in adults with known intermediate-stage hepatocellular carcinoma, according to the company. Lipiodol acts as a contrast agent, a drug-eluting vehicle, and a dual arterioportal transient embolic for cTACE procedures.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking